

REMARKS

Claims 1-10 have been cancelled without prejudice or disclaimer to pursue this subject matter in continuation or divisional applications. New claims 11-66 have been added. Upon entry of the foregoing amendment, claims 11-66 will be pending.

Applicants respectfully submit that no prohibited new matter has been introduced by the amendments. Written description support for the new claims can be found throughout the specification and specifically the original claims (1-10). Support for “the antigenically active substance is one or more natural antigens, synthetic antigens, antigen mimotopes, or a combination thereof” can be found throughout the specification, but specifically on pages 4-6 and original claims 6-8.



Applicant believes that the above-referenced application is in condition for allowance. Early notice of allowance to that effect is respectfully requested.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application, including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 13-3250, reference No. 33677.00600. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F. R. § 1.136(a)(3).

If the Examiner finds that a telephone conference would further prosecution of this application, the Examiner is invited to contact the undersigned at 202-835-7553.

Respectfully submitted,

MILBANK, TWEED, HADLEY & McCLOY LLP

By:  
Einar Stole
Reg. No. 47, 272

Dated: July 15, 2004

MILBANK, TWEED, HADLEY & McCLOY LLP
1825 Eye Street, NW Suite 1100
Washington, DC 20006
202-835-7500